NewsMedicinal CannabisA Golden Ambition For Medical Cannabis Industry?

A Golden Ambition For Medical Cannabis Industry?

-

CREATING standardised medicine is the gold standard for the cannabis industry but the nature of the plant makes this difficult, says a leading expert.

Dr Barbara Pacchetti, of U.K. company EMMAC Life Sciences, speaking at Cannabis Europa, described cannabis as an ‘unconventional medicine’.

“The aim is for standardised medicine, and this would be the peak of Everest. Doctors are not comfortable with anything else, but with cannabis we have the plant’s entourage effect and this leads to a lot of questions and grey areas in relation to variability.

“For pharma companies, isolates are the gold standard, but there is variability with cannabis due to the different cannabinoids, plant strains, the terpenes and the flavonoids and this means we have to do more work to understand this entourage; the genetics.”

Speaking on day one of the the conference, last year, in a debate on ‘Cannabis-Based Medicines’ she said it would initially be difficult to bridge the gap left by a lack of research, due to the prohibition of cannabis over the last 60 years.

And she added: “We are just the beginning to learn and to connect with regulators, the health authorities and this will allow us to make the right cannabis medicines available to the public.”

Dianna Gutierrez, of Spanish firm Linneo Health, agreed there was much research to be done. She said it was looking at selecting different cannabis molecules and products to target different diseases.

She added: “We have to change way we produce, grow and manufacture a medicine and we need the money; huge investment from funds to get the quality of drug we require.”

Aras Azadian, of Canadian company Avicanna, said physicians like to have 

straight-forward medicines they can rely on, and this is a challenge the cannabis industry can rise to.

“They depend on one or two, high-standard products. When prescribing, it’s a case of taking it in stages – crawl, walk, run – but patients may see things differently and want different strains and flowers, for example.

“Patients have become accustomed to having the same level of consistency in their medicines, but the variability of the cannabis plant makes this difficult to achieve. 

“Cannabis medicine needs to have the highest standards; Quality assurance, and standardisation of cannabis medicine is necessary, achievable, and the responsibility of the people in this room.”


Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Plans Unveiled For First National Health Service-Backed Medical Cannabis Clinical Trial

AFTER launching a patient registry earlier this year further signs the UK’s National Health Service is warming to cannabis...

Reakiro – Europe’s Leading CBD And Hemp Brand – Delivers The Complete B2B & B2C Package

IN a time when CBD products are becoming unavoidable in the health, wellness and fitness industries, it is more...

Is Luxembourg’s Quest To Introduce An Adult-Use Cannabis Programme Going Up In Smoke?

CONCERNS over Luxembourg’s intent to become the first European country to legalise adult-use cannabis have emerged. In an interview on...

Cannabis Is Now A Compelling Opportunity For The Main Tobacco Companies

International cannabis expert, Barbara Pastori, of Prohibition Partners shares her thoughts on why cannabis is a compelling opportunity for...

Oxford Cannabinoid Technologies Holdings Sign Exclusive Worldwide License Agreement With Canopy Growth

Oxford Cannabinoid Technologies Holdings plc (OCTP), the holding company of Oxford Cannabinoid Technologies Ltd (“OCT”) (together, the “Group”), a...

With Global Cannabis Cultivation Capacity Set To Outstrip Demand One Hundredfold – What Happened To The ‘Green’ Rush?

CANNABIS investors need to be wary when it comes to cultivation, says Oliver Zugel, Founder and CEO FoliuMed Holdings. Where...

Must read

Plans Unveiled For First National Health Service-Backed Medical Cannabis Clinical Trial

AFTER launching a patient registry earlier this year further...

Is Luxembourg’s Quest To Introduce An Adult-Use Cannabis Programme Going Up In Smoke?

CONCERNS over Luxembourg’s intent to become the first European...

You might also likeRELATED
Recommended to you